Sanofi to acquire Inhibrx-101 for around $2.2B



French pharmaceutical company Sanofi S.A. announced in a written statement on Tuesday its decision to acquire Inhibrx-101, an Inhibrx Inc. drug development project, for around $2.2 billion.

According…

About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento